Skip to content
‹ Back to IndustriesHealthcare

Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
Surfacide experiences 500% Increase in Demand of Their Coronavirus Killing UV Robots

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

(Waukesha, WI)—January 5, 2021 – Surfacide®, the leader in hospital-grade, triple-emitter UV-C robot technology, is excited to announce they’ve moved to a larger facility in Waukesha, WI to accommodate rapid business growth at more than 500% in the past year. As we move into our new normal, germ-fighting, COVID-19 killing “robots” is being deployed everywhere from hospitals, nursing homes, restaurants, hotels, gyms to commercial office spaces, tourist attractions, and professional sports stadiums. Surfacide has been a trusted leader in UV decontamination for over ten years due to its world’s only patented Helios® Triple-Emitter System of three virus-zapping robots.

Surfacide is actively being used throughout the world in over 500 leading healthcare facilities, children’s hospitals, nursing homes, correctional facilities, dental offices, hotels, restaurants, commercial businesses and more around the world. Such facilities include the Seattle Space Needle, Beachbody Studios, Children’s Hospital of Los Angeles and locally at Children’s Hospital of Wisconsin, Froedtert Medical College—Milwaukee and Aspirus Wausau Hospital. The company’s UV-C technology is scientifically validated to inactivate coronavirus–the family of virus that make up SARS-CoV-2 and COVID-19.

Surfacide’s new location is at N918 Northmound Dr., STE. 300 Waukesha, WI 53186 and the company’s new facility is more than 75,000 sq-ft, three times the size of their previous location. The company was started in a one-room office in 2010 and has experienced incredible and consistent growth every year since its inception. The expansive new building space will offer much needed space for Surfacide’s expanding team and to meet the huge increase in demand for their UV system since the pandemic hit. The facility will continue to house the company’s manufacturing and distribution arm, as well as a global training center, a state-of-the-art UV robot simulation room, conference rooms and offices.

Gunner Lyslo, Founder & CEO of Surfacide shares his excitement for the new space: “During the pandemic, we are fortunate to have grown our team and provide a proven UV-C technology that has tremendously impacted healthcare facilities, nursing homes, dental offices, and more in fighting the COVID-19 virus,” says Lyslo. “This year the importance of infection prevention has been paramount, and we expect to see that course continue in years to come. For as long as our communities need safety and protection, Surfacide will continue to evolve and be there to assist those who need it most.”

 About Surfacide

 Surfacide LLC and Surfacide Manufacturing Inc. are located in Waukesha, WI and produce multiple emitter UV-C systems. Surfacide is the only patented triple emitter UV-C system, providing the most efficient and flexible solution in the fight against viruses and bacteria that cause hospital-acquired infections. Hundreds of hospitals worldwide are using Surfacide technology to provide an extra layer of protection for patients and healthcare workers. Surfacide’s evidence-based UV-C solution reaches more surfaces, reduces shadowed areas, and requires less labor for a quicker turnaround time and better efficacy. Learn more about Surfacide by visiting https://surfacide.com or calling (844)-390-3538.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Capsa's RoboPharma HV Wall is the first central fill system confirmed compatible with Parcel Health's paper vials

Capsa's RoboPharma HV Wall is the first central fill system confirmed compatible with Parcel Health's paper vials

Capsa Healthcare says its RoboPharma HV Wall is the first central fill automation system confirmed to fill Parcel Health’s Tully Tube, a paper prescription vial. The confirmation matters because central fill and mail order sites can only use containers their machines can handle—but this applies to the HV Wall specifically and is not a named production deployment. Buyers can see the vials at ASHP Midyear, Dec. 6–9.

  • 01A central fill site can't switch to a paper vial its automation can't handle. Confirmed machine compatibility is the gate, and the RoboPharma HV Wall is the first system through it for the Tully Tube.
  • 02The up to 71 percent plastic reduction per unit is a ceiling measured against a similar-size plastic vial, so operators modeling sustainability targets should ask for the comparison basis for their own vial sizes.

Nov 20, 2026

Luminopia's CEO says payer churn slows coverage and can require patching first

Luminopia's CEO says payer churn slows coverage and can require patching first

Luminopia co-founder and CEO Scott Xiao told HLTH's Partner Highlight series that short payer member tenure and a fragmented Medicaid leave pediatric amblyopia neglected. A 2025 JMCP payer roundtable recommended covering the FDA-authorized therapy but allowed step-edits, while PEDIG data show two-hour patching adds about 1.1 lines of acuity. Cleveland Clinic registry data report 1.8 lines of gain in severe cases.

  • 01A 2025 payer roundtable in the Journal of Managed Care & Specialty Pharmacy recommended plans cover Luminopia, yet said step-edits and letters of exception may still be required, with more than 9,000 prescriptions written since November 2022.
  • 02PEDIG's ATS05 trial put two hours of daily patching at 1.1 lines of gain over five weeks versus 0.5 lines for glasses alone, while a 2015 AAO review tied patching's poor compliance to social stigma.
  • 03S.1702, the Access to Prescription Digital Therapeutics Act of 2025, has sat in the Senate Finance Committee since May 8, 2025, leaving coverage negotiated plan by plan.

Nov 19, 2026

AHA and BD's 10-hospital pilot tests who acts on surgical blood pressure readings

AHA and BD's 10-hospital pilot tests who acts on surgical blood pressure readings

The American Hospital Association, West Health and BD will add continuous blood pressure monitoring to surgical care at 10 hospitals, with Vizient measuring results. The pilot tests the workflow around the device: who notices a change, who acts and who hands it off. Whether it spreads depends on cost after startup funding ends.

  • 01A monitor running in two operating rooms can support two different decisions, so device usage counts can say little about whether continuous blood pressure monitoring actually changed surgical care.
  • 02Hospitals evaluating continuous monitoring may already own idle devices; learning why they sit unused, whether training time or an awkward spot in the workflow, points to a different fix than a new purchase order.
  • 03A playbook is expected in roughly a year, aiming to define essential steps while leaving room for smaller or resource-limited hospitals—such as those without 24/7 pharmacy coverage—to adapt workflows locally.

Nov 19, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512